NASDAQ:ADAP Adaptimmune Therapeutics - ADAP News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. $1.10 +0.01 (+0.92%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.06▼$1.1250-Day Range$1.09▼$1.8752-Week Range$1.01▼$2.65Volume562,736 shsAverage Volume1.02 million shsMarket Capitalization$170.13 millionP/E RatioN/ADividend YieldN/APrice Target$6.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAP Media Mentions By Week ADAP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADAP News Sentiment▼0.580.67▲Average Medical News Sentiment ADAP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADAP Articles This Week▼52▲ADAP Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAdaptimmune Therapeutics plc (NASDAQ:ADAP) Receives Consensus Rating of "Moderate Buy" from Analystsmarketbeat.com - March 24 at 10:25 AMAdaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at Bryan, Garnier & Coamericanbankingnews.com - March 25 at 5:48 AMSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of TCR2 Therapeutics Inc. (TCRR)marketwatch.com - March 24 at 7:45 AMAdaptimmune Therapeutics (NASDAQ:ADAP) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - March 16 at 5:06 AMAnalysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), Foghorn Therapeutics (FHTX) and Rain Therapeutics (RAIN)markets.businessinsider.com - March 10 at 3:15 PMNews Flash: Analysts Just Made A Huge Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecastsfinance.yahoo.com - March 8 at 10:20 AMAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - March 8 at 10:20 AMTCR Therapeutics Shares Rise, Adaptimmune ADS's Slide on Tie-Upmarketwatch.com - March 6 at 5:37 PMAnalysts Are Bullish on Top Healthcare Stocks: CTI BioPharma (CTIC), Adaptimmune Therapeutics (ADAP)markets.businessinsider.com - March 6 at 5:37 PMAdaptimmune to acquire Boston-area cell therapy company TCR² Therapeuticsbizjournals.com - March 6 at 5:37 PMAdaptimmune Agrees To Merge With Another Cell Therapy Focused Companyfinance.yahoo.com - March 6 at 5:37 PMAdaptimmune to Buy TCR Therapeutics in $103M Stock Swap >ADAP TRCCmarketwatch.com - March 6 at 10:01 AMAdaptimmune Craters after Acquiring TCR² Therapeuticsmsn.com - March 6 at 10:01 AMAdaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Updatefinance.yahoo.com - March 6 at 10:01 AMNeuroblastoma Treatment Industry (Views and Position) 2023-2028marketwatch.com - March 6 at 5:01 AMAdaptimmune Therapeutics's Earnings Outlookmsn.com - March 3 at 6:35 PMTCR-Based Antibody Market 2023: Growth by 2029 Top Players with Opportunitiesmarketwatch.com - February 28 at 8:34 AMAdaptimmune Therapeutics Stock (NASDAQ:ADAP), Quotes and News Summarybenzinga.com - February 26 at 11:15 PMAnalysts Offer Insights on Healthcare Companies: Infinity Pharma (INFI) and Leap Therapeutics (LPTX)markets.businessinsider.com - February 23 at 5:19 PMAnalysts Are Bullish on These Healthcare Stocks: Biora Therapeutics (BIOR), IN8bio (INAB)markets.businessinsider.com - February 23 at 5:19 PMAdaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023finance.yahoo.com - February 22 at 12:52 PMAdaptimmune Announces Changes to Board of Directorsfinance.yahoo.com - February 16 at 9:18 AMAn Overview of Neuroblastoma Treatment Market, Major Participants, and Prospects by 2028marketwatch.com - January 18 at 2:04 PMPublication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcomafinance.yahoo.com - January 9 at 10:23 AMEven after rising 48% this past week, Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are still down 72% over the past five yearsfinance.yahoo.com - January 8 at 12:21 PMPneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directorsbenzinga.com - January 6 at 8:48 AMExpert Ratings for Adaptimmune Therapeuticsmarkets.businessinsider.com - January 5 at 2:28 PMVerismo Therapeutics Expands Quality and Compliance Teammarkets.businessinsider.com - January 3 at 2:05 PM3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buyingfinance.yahoo.com - December 27 at 2:52 PMAdaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcomafinance.yahoo.com - December 23 at 2:05 PMHedge funds investors may adopt severe steps after Adaptimmune Therapeutics plc's (NASDAQ:ADAP) latest 20% drop adds to a year lossesfinance.yahoo.com - December 10 at 5:10 PMData from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistentfinance.yahoo.com - November 18 at 8:13 AMSVB Securities Reaffirms Their Hold Rating on ImmunoGen (IMGN)markets.businessinsider.com - November 16 at 2:22 PMReCode Therapeutics Establishes Scientific Advisory Boardfinance.yahoo.com - November 14 at 8:19 AMNew Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)finance.yahoo.com - November 13 at 5:01 PMLab notes: Adaptimmune to reduce workforce; NRx completes $11M debt financingfinance.yahoo.com - November 11 at 2:34 PMVeterans of Influence Awards 2022: John Lunger, Adaptimmune Therapeuticsbizjournals.com - November 10 at 6:32 PMAdaptimmune Therapeutics Third Quarter 2022 Earnings: Beats Expectationsfinance.yahoo.com - November 10 at 6:32 PMAdaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Businessfinance.yahoo.com - November 8 at 5:56 PMWhy Adaptimmune Therapeutics Stock Is Glowing Green Todayfinance.yahoo.com - November 8 at 5:56 PMAdaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancersfinance.yahoo.com - November 8 at 9:33 AMAdaptimmune Reports Third-Quarter Financial Results and Business Updatefinance.yahoo.com - November 8 at 9:33 AMAdaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022finance.yahoo.com - October 27 at 5:35 PMAdaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSKfinance.yahoo.com - October 25 at 11:15 AMT-Cell Immunotherapy Market Insights : Industry dynamics, New Technologies and Forecast to 2027marketwatch.com - September 29 at 2:34 PMMizuho Securities Reaffirms Their Hold Rating on Incyte (INCY)markets.businessinsider.com - September 27 at 7:27 AMAfter a 24% dip, insiders are undoubtedly glad they sold Adaptimmune Therapeutics plc (NASDAQ:ADAP)nasdaq.com - September 26 at 7:19 PMAdaptimmune Therapeutics: Depressed Despite Upcoming BLAseekingalpha.com - September 20 at 12:33 PMAdaptimmune Therapeutics (ADAP) Presents At ESMO Congress 2022 - Slideshowseekingalpha.com - September 16 at 7:32 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adaptimmune Therapeutics plc - ADAPbenzinga.com - September 12 at 6:08 PMADRs End Higher, Argo Blockchain and Adaptimmune Therapeutics Trade Activelymorningstar.com - September 10 at 9:08 PM Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:ADAP) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.